Regenerex Pharma Files Q2 2024 10-Q

TL;DR

Regenerex Pharma (RGPX) dropped its Q2 10-Q. Check financials.

AI Summary

Regenerex Pharma, Inc. filed its quarterly report for the period ended June 30, 2024. The company, previously known as Peptide Technologies, Inc. and Eternelle Skincare Products Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. The filing details financial information and operational updates for the second quarter of 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational status of Regenerex Pharma, Inc. for the second quarter of 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Regenerex Pharma faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 20240630 — Period End Date (The report covers the financial performance up to this date.)
• 20240807 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• REGENEREX PHARMA, INC. (company) — Filer
• PEPTIDE TECHNOLOGIES, INC. (company) — Former company name
• Eternelle Skincare Products Inc. (company) — Former company name
• 20240630 (date) — Period of report
• 20240807 (date) — Filing date
• 0001357878 (company) — Central Index Key

FAQ

Key Financial Figures

• $0.001 — anding at August 7, 2024 Common stock, $0.001 par value 278,255,910 "Explanatory N
• $2,400,000 — million four hundred thousand dollars ($2,400,000) note payable that is due August 17, 20
• $10,000,000 — aised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months, or
• $5,888,410 — tions and had an accumulated deficit of $5,888,410 as of June 30, 2024. The Company also h
• $500 — s are capitalized while purchases under $500 are expensed as incurred. Right of Use
• $51,600 — mounts totaling approximately $ 38,500 ($51,600 Canadian Funds) that came due during th
• $55,980 — cipal amount of approximately $ 41,800 ($55,980 Canadian Funds) which included the prin
• $4,380 — ued interest of approximately $ 3,300 ($4,380 Canadian Funds.) These notes are unsecu

Filing Documents

• ixform10q.htm (10-Q) — 369KB
• exhibit31-1.htm (EX-31.1) — 11KB
• exhibit31-2.htm (EX-31.2) — 11KB
• exhibit32-1.htm (EX-32.1) — 4KB
• exhibit32-2.htm (EX-32.2) — 4KB
• regenerexlogo.gif (GRAPHIC) — 6KB
• 0001472375-24-000074.txt ( ) — 2158KB
• rgpx-20240630.xsd (EX-101.SCH) — 20KB
• rgpx-20240630_cal.xml (EX-101.CAL) — 30KB
• rgpx-20240630_def.xml (EX-101.DEF) — 99KB
• rgpx-20240630_lab.xml (EX-101.LAB) — 160KB
• rgpx-20240630_pre.xml (EX-101.PRE) — 137KB
• ixform10q_htm.xml (XML) — 150KB

forward-looking statements are based on a series of expectations, assumptions,

forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these

forward-looking statements. Actual results or events could differ materially

forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: our ability to add new customers; the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows; the potential benefits of and our ability to maintain our relationships, and establish or maintain future collaborations or strategic relationships or obtain additional funding; our marketing capabilities and strategy; our ability to maintain a cost-effective program; our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; our competitive position, and developments and projections relating to our competitors and our industry; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and the impact of laws and regulations. All of our forward-looking each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the "SEC") could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to upd

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Balance Sheets 5 6 7 8

Notes to Financial Statements

Notes to Financial Statements 9 Item 2. Management Discussion & Analysis of Financial Condition and Results of Operations 16 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21 PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mining Safety Disclosures 23 Item 5 Other Information 23 Item 6. Exhibits 23 CERTIFICATIONS 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 4 PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS REGENEREX PHARMA, INC. BALANCE SHEETS (UNAUDITED) June 30, 2024 March 31, 2024 ASSETS Current Assets Cash and equivalents $ — $ 372 Prepaid expenses 2,357 2,540 Total Current Assets 2,357 2,912 Website, net of accumulated amortization of $ 29,986 and $ 29,272 , as of June 30, 2024 and March 31, 2024, respectively 614 1,328 Furniture and computer equipment, net of accumulated depreciation of $ 2,030 and $ 1,600 as of June 30, 2024 and March 31, 2024 5,667 6,097 Right of use assets 720,452 756,343 Total Assets $ 729,090 $ 766,680 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable $ 160,696 $ 116,760 Related party advances 5,290 3,690 Accrued compensation 608,732 511,847 Other accrued liabilities 106,971 97,251 Current portion of notes payable to shareholder 604,609 475,050 Current portion of notes payable to related parties 168,726 110,500 Current portion of notes payable 2,584,232 2,400,000 Current portion of lease liabilities 174,259 128,264 Total Current Liabilities 4,413,515 3,843,362 Notes payable to shareholder, net of current portion — 119,114 Notes payable, net of current portion — 184,232 Lease liabilities, net of current portion 628,964 681,798 Total Liabilities 5,042,479 4,828,506 Commitments and Contingencies (Note 7) - - Stockholders' Deficit Common stock: $ 0.001 par value: 675,000,000 shares authorized: 278,255,910 , and 278,225,910 issued and outstanding at June 30, 2024 and March 31, 2024 278,256 278,226 Additional paid-in capital 1,296,765 1,275,798 Accumulated deficit ( 5,888,410 ) ( 5,615,850 ) Total Stockholders' Deficit ( 4,313,389 ) ( 4,061,826 ) Total Liabilities and Stockholders' Deficit $ 729,090 $ 766,680 The accompanying notes are an integral part of these unaudited financial statements. 5 REGENEREX PHARMA, INC.

financial statements do not include any adjustments related to the recoverability

financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under Accounting Standards Codification ("ASC") 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran's administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification ("ASC") Topic 260 " Earnings per Share " which requires dual presentation of basic earnings per share ("EPS") and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per

View Full Filing

View this 10-Q filing on SEC EDGAR